A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2011
At a glance
- Drugs Gefitinib (Primary)
- Indications Lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 21 Nov 2009 New trial record